NV-5138 C AR Degrader-4 TFA 27)28)10-16(14)30-18

27)28)10-16(14)30-18

InChi: InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H

Smiles: CC1=CC=C(C=C1NC1=CC2NC(=O)/C(=C\C3=CC=CN3)/C=2C=C1)NC(=O)NC1=CC(=CC=C1F)C(F)(F)F

Double-blind study of pardoprunox

NV-5138 C AR Degrader-4 TFA 27)28)10-16(14)30-18NV 5138 is an orally and centrally active small molecule drug for the treatment of major depressive disorder (MDD). It directly and selectively activates the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway by binding to and modulating sestrin2, a leucine amino acid sensor and upstream regulatory pathway. The mTORC1 pathway is the same signaling pathway that the NMDA receptor antagonist ketamine activates in the medial prefrontal